Streetbeat News

Earnings

SIG

Signet Jewelers (NYSE:SIG) reported Q4 adjusted EPS of $6.73, surpassing the $6.35 estimate, marking a 21.92% year-over-year increase. However, its sales of $2.50B fell short of the $2.54B estimate, a 6.34% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:51 am

JILL

J.Jill anticipates its Q1 net sales to increase in the low to mid-single-digit percentage range, indicating a positive outlook for the company's financial performance in the near term.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:50 am

JILL

J.Jill projects its fiscal year 2024 net sales to remain stable or experience a slight increase in the low-single digits.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:49 am

JILL

J.Jill reported a significant increase in Q4 adjusted EPS to $0.23 from $0.11 YoY, with sales reaching $149.45M, surpassing the $147.40M estimate. This represents a 1.22% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:46 am

PDD

PDD Holdings shares are trading higher following the announcement of their Q4 FY23 results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:43 am

PNM

PNM Resources Management announced plans to meet with investors and confirmed its ongoing EPS guidance for 2024 to be in the range of $2.65-$2.75, aligning with the estimated $2.68.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:37 am

PDD

PDD Holdings reported Q4 adjusted earnings per ADS of $2.40, surpassing the $1.60 estimate, a 98.35% increase from last year. Sales reached $12.52B, beating the $11.01B estimate, marking a 116.84% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:32 am

BNTX

BioNTech's stock is trading lower following the announcement of disappointing Q4 FY23 earnings and less optimistic guidance for FY2024.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:24 am

BNTX

BioNTech forecasts FY2024 sales to be between €2.5B and €3.1B, with R&D expenses projected at €2.4B-€2.6B, SG&A expenses at €700M-€800M, and capital expenditure estimated to be €400M-€500M.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:20 am

BNTX

BioNTech (NASDAQ:BNTX) reported Q4 GAAP EPS of $2.04, missing the $2.64 estimate, and sales of $1.59B, below the $1.99B estimate. This represents a significant decrease from the previous year, with earnings down 78.36% and sales down 63.54%.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:16 am